Omeros Announces First Commercial Sales of YARTEMLEA
Business Wire (Tue, 27-Jan 9:00 AM ET)
Omeros Announces New Date for YARTEMLEA Approval Conference Call
Business Wire (Fri, 26-Dec 6:36 PM ET)
OMER Call Spread Buyers Net 26.4% in a Day as FDA Approval Sparks Bullish Surge
Market Chameleon (Wed, 24-Dec 6:35 AM ET)
FDA Approval of Omeros’ YARTEMLEA Establishes New Standard of Care for TA-TMA
Market Chameleon (Wed, 24-Dec 4:16 AM ET)
FDA Approves Omeros' YARTEMLEA - First and Only Therapy Indicated for TA-TMA
Business Wire (Wed, 24-Dec 9:00 AM ET)
Market Chameleon (Mon, 1-Dec 4:04 AM ET)
Business Wire (Mon, 1-Dec 8:30 AM ET)
Omeros Corporation Reports Third Quarter 2025 Financial Results
Business Wire (Thu, 13-Nov 4:11 PM ET)
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Business Wire (Tue, 11-Nov 8:30 AM ET)
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of February 4, 2026, OMER stock price declined to $11.51 with 1,314,163 million shares trading.
OMER has a beta of 0.52, meaning it tends to be less sensitive to market movements. OMER has a correlation of 0.01 to the broad based SPY ETF.
OMER has a market cap of $816.06 million. This is considered a Small Cap stock.
Last quarter Omeros reported $0 in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-312,500 and exceeded earnings estimates by $.18.
In the last 3 years, OMER traded as high as $17.65 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
OMER has outperformed the market in the last year with a return of +36.5%, while the SPY ETF gained +16.0%. In the last 3 month period, OMER beat the market returning +60.5%, while SPY returned +0.7%. However, in the most recent 2 weeks OMER has underperformed the stock market by returning -6.1%, while SPY returned +1.3%.
OMER support price is $11.12 and resistance is $12.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
